Efforts to rapidly scale up access to human immunodeficiency virus (HIV) care and treatment have been successful at initiating large numbers of individuals on antiretroviral therapy (ART). The greatest increase has occurred in sub-Saharan Africa, home to 69% of the estimated 34 million people living with HIV/AIDS worldwide, where ART access has increased from 100 000 people on ART in 2003 to 6.2 million in 2011 [1] . Despite considerable success in expanding access to ART, most HIV-infected people in sub-Saharan Africa initiate ART in the advanced stages of HIV disease, resulting in substantial early mortality [2] , more complicated and costly clinical management [3] , lag in CD4+ cell-count response [4] , and missed opportunities to prevent onward HIV transmission [5] .
By 2011, approximately 56% of HIV-infected people in need of treatment in the sub-Saharan African region had accessed ART [1] . In recent years, most national HIV treatment programs in the region have adopted the expanded 2010 World Health Organization (WHO) criteria for ART eligibility of CD4+ count < 350 cells/µL (irrespective of WHO disease stage) or WHO disease stage 3 or 4 [6] . Although national guidelines are an important reference point, most individuals in sub-Saharan Africa have historically initiated ART at levels well below prevailing guideline thresholds [7] . Studies that have examined trends over time suggest that median CD4+ counts at ART initiation are increasing in most sub-Saharan African countries, but even in 2010 they remained below 200 cells/µL in most low-and middle-income countries [8] [9] [10] [11] . The low CD4+ count at ART initiation may reflect, among other things, the need to prioritize the sickest individuals over those who are less sick [12] .
The objectives of this study were to assess trends in the median CD4 count and proportion of HIV-infected individuals who initiated ART with advanced HIV disease between 2006 and 2011 in 4 sub-Saharan countries. We also examined individual-level factors associated with advanced HIV disease at ART initiation among patients starting ART in 2011.
METHODS
We examined longitudinal patient-level data from the pre-ART phase of care on 334 557 adults (aged ≥15 years) who enrolled in HIV care and treatment programs at 132 HIV care clinics in Kenya, Mozambique, Rwanda, and Tanzania between 2006 and 2011. The distribution of the number of facilities and persons enrolled in care by country was as follows: Kenya: 61 facilities, n = 82 318; Mozambique: 28 facilities, n = 187 992; Rwanda: 23 facilities, n = 24 378; and Tanzania: 20 facilities, n = 39 869. The clinics included are part of national ART programs and were supported during the study period by ICAP at Columbia University, a President's Emergency Plan for AIDS Relief (PEPFAR) implementing partner.
Data Sources
Patient information routinely collected at enrollment in HIV care and during each clinic visit was documented by clinicians on standard forms used nationally. Trained data clerks routinely abstracted relevant data from patients' medical charts for baseline and follow-up clinic visits and entered them into electronic databases. Data quality assessments were done every 6 months to assess for completeness and accuracy of data entry. Information was de-identified for analysis.
Definitions and Outcomes
ART initiation at the facilities was based on national guidelines within each country. Advanced HIV disease at enrollment in HIV care or ART initiation was defined as having a CD4+ count < 100 cells/μL or WHO disease stage 4. We defined "at enrollment" as any measurement within 1 month of enrollment into HIV care and "at ART initiation" as any measurement 3 months before or 1 month after ART initiation. In instances where CD4+ count or WHO disease stage were missing at ART initiation under the above definition, we used the highest WHO disease stage prior to initiation of ART and any prior CD4+ count < 100 cells/µL. A substantial proportion of patients still had missing information on CD4+ count and WHO disease stage at enrollment and ART initiation. These patients were included in our analyses using "missing/unknown" categories for CD4+ count, WHO disease stage, and advanced HIV disease at enrollment and at ART initiation, accordingly. Patients for whom there was no documentation of tuberculosis treatment were assumed not to be on treatment. Having a gap in pre-ART HIV care was defined as not having had a clinic visit for 12 or more months between enrollment and ART initiation.
Statistical Analysis
We examined characteristics of all patients receiving care at enrollment and at ART initiation. We then assessed the proportion of patients with advanced HIV disease at enrollment and at ART initiation in 2011 compared with 2006. Trends over time were examined in the proportion with advanced disease at enrollment into care and ART initiation, as well as the median CD4+ count at enrollment and ART initiation from 2006 to 2011 by sex. We also identified factors associated with ART initiation at advanced HIV disease in 2011, irrespective of year of enrollment in HIV care, using generalized linear models (GENMOD procedure in SAS with the log link function) to estimate the adjusted odds ratio (AOR), adjusting for age and other covariates and accounting for clustering of observations within clinics. In sensitivity analyses, multiple imputations for the marital status, point of entry, and ART eligibility variables were conducted to assess the impact of missing data on the final multivariate model. Sensitivity analyses were also conducted to evaluate the extent to which each of the 4 countries individually influenced the overall results in the final model. Statistical analyses were carried out using SAS, version 9.2 (SAS Institute, Cary, NC).
Ethical Considerations
The national ethics committees in each country, the Columbia University Medical Center institutional review board, the US Centers for Disease Control and Prevention, and the US PEPFAR Office of the Global AIDS Coordinator approved the use of data for this study.
RESULTS

Characteristics of All Adults Enrolled in Care
Sociodemographic characteristics of the 334 557 adults enrolled in care and the 149 032 who eventually initiated ART during 2006 and 2011 are presented in Table 1 . At enrollment into care, two-thirds were women (10% of them documented as being pregnant). The overall median age was 33 years (interquartile range [IQR] , 27-41) and nearly half were married or living with a partner. For ART patients, two-thirds were women (6% documented as being pregnant), the median age was 35 years (IQR, 29-43), and 46% were married or living with a partner.
Clinical and Immunological Characteristics at Enrollment and ART Initiation
Of the 85% of patients with recorded information on CD4+ count and/or WHO disease stage at enrollment into care, 19% were classified as enrolling into care with advanced HIV disease ( Table 2 ). Among the 53% of all patients and 65% of those who initiated ART with information on CD4+ count at enrollment, the median CD4+ counts were 259 cells/µL (IQR, 117-461) and 173 cells/µL (IQR, 80-285), respectively. Of the 74% of patients with WHO disease stage information at enrollment, 45% had WHO disease stage III or IV disease. At enrollment into care, 32% were ART eligible, while 17% had unknown eligibility (missing CD4+ count and/or WHO disease stage at enrollment). Among those who initiated ART during the observation period, more than half (54%) were ART eligible at enrollment.
Among those who initiated ART, 96% had information on CD4+ count and/or WHO disease stage at ART initiation, of those 35% had advanced HIV disease. Among the 71% with CD4+ count information, the median CD4+ count was 155 cells/µL (IQR, 72-238). Of the 91% with information on WHO disease stage at ART initiation, 59% had WHO stage III or IV disease. Finally, 3% were documented to be on tuberculosis treatment at ART initiation.
Change Over Time in Median CD4+ Counts and Proportion Enrolling in Care and Initiating ART With Advanced HIV Disease
The proportion of patients enrolling in care with advanced HIV disease decreased from 20% to 18% (P trend < .001) from 2006 to 2011 ( Figure 1A ), while among patients who initiated ART, the proportion enrolling in care with advanced HIV disease decreased from 36% to 22% (P trend < .001; Figure 1B ). The proportion of patients who initiated ART with advanced HIV disease decreased from 42% to 29% (P trend < .001) from 2006 to 2011; decreases were observed among both males and females ( Figure 1C Number of sites = 132.
Abbreviations: ART, antiretroviral treatment; IQR, interquartile range; PITC, provided initiated testing and counseling; PMTCT, prevention of mother-tochild transmission; VCT, voluntary counseling and testing.
cells/μL (IQR, 86-279; P < .001; an increase of 10 cells per year; Figure 2C ). The proportion with nonmissing CD4+ count information at ART initiation did not change appreciably over time (70% in 2006 and 68% in 2011). Differences were observed in the trends of median CD4+ count at ART initiation, with Kenya and Rwanda experiencing the largest increases over time ( Figure 3 ). In 2011, the median CD4+ count at ART initiation was significantly different by country (P value < .001).
There was a significant decrease in the overall proportion of patients enrolling in care with advanced HIV disease between 2006 and 2011 (20% vs 17%; P < .05), as well as among patients aged 15-25 years (11% vs 15%) and 26-35 years (17% vs 21%), those living with a partner (14% vs 19%), those not in union (18% vs 23%), those in Mozambique (21% vs 17%), and those in Tanzania (22% vs 33%). Table 3 However, despite the decrease in the proportion of patients enrolling and those initiating ART with advanced HIV disease among both genders ( Figure 1A and 1C) , men remained at higher risk compared with women, and this disparity appears to be widening with time. Specifically, there was an increase in the odds of advanced HIV disease at enrollment into care for males vs females from 1. Results of sensitivity analyses using multiple imputations of missing data were highly consistent in terms of the direction, magnitude, and significance of associations to those presented in Table 4 . Sensitivity analyses were also conducted excluding each of the 4 countries from the final model and including those with missing CD4 count and WHO disease stage as initiating ART at advanced HIV disease or not. Results from these models were also consistent with those in Table 4 .
DISCUSSION
Our study showed a substantial decrease in the proportion of patients who initiated ART with advanced disease between 2006 and 2011 at 132 clinical care facilities that provide care in Kenya, Mozambique, Rwanda, and Tanzania (from 42% to 29%). That the proportion of patients initiating ART in the advanced stages of HIV decreased, with little change in the proportion of those with advanced disease at enrollment (from 20% to 18%), suggests that many clinics and settings included in our analyses are making progress in treating the sickest individuals in their catchment areas, but that intensified and targeted efforts aimed at earlier diagnosis and linkage to care are needed. The median CD4+ count increased over time both at enrollment into care as well as at ART initiation (from 238 to 286 cells/μL and from 125 to 185 cells/μL, respectively, or about 10 cells/year). While the increase is encouraging, the rate of increase observed in our sample is discouragingly slow, such that it would be more than 15 years before the median CD4 count at ART initiation reached 350 cells/µL (ie, when only half of patients initiating ART would do so at the current recommended CD4 threshold). Of concern is that the well-documented male-female disparity in the risk of initiating ART with advanced HIV disease in the region appears to be worsening with time. Finally, those who experience a ≥12 month gap in pre-ART care were more likely to initiate ART with advanced HIV disease, independent of other factors. These findings have clear implications for program implementers in the sub-Saharan African region. Among patients who initiated ART between 2006 and 2011, 29% had advanced HIV disease at enrollment in care and 35% at ART initiation, suggesting that most of those who initiated ART at advanced HIV disease did so because they had enrolled in care with advanced HIV disease. Enrollment into care with advanced HIV could be due to late diagnosis or delayed linkage to care once diagnosed [7, [13] [14] [15] . Given the moderate decline in the proportion enrolling in HIV care with advanced disease, our results highlight the urgent need to redouble efforts aimed at expanding HIV testing coupled with timely linkage to care, with the aim of promoting earlier ART initiation. The substantial variability across facilities in the proportion initiating ART with advanced HIV disease underscores the possibility that important and potentially modifiable determinants of this outcome operate beyond the individual level, such as the clinic and contextual levels. This has been suggested by our team Figure 1 . Proportion of patients with advanced human immunodeficiency virus disease at enrollment among all patients (A), at enrollment among those that initiated antiretroviral treatment (ART) (B), and at ART initiation among patients initiating ART by sex (C) (132 sites). Excluding patients who did not have enough information about their status at enrollment and ART initiation (ie, no CD4+ count or no World Health Organization disease stage).
[7, 9, 10] as well as others [16] , and future studies should continue to elucidate higher-level effects that could suggest avenues for clinic-and catchment area-level interventions that promote earlier ART initiation.
The increase in the median CD4 count at ART initiation over time is likely due to progress in treating the sickest individuals in the clinic catchment areas and, in some cases (eg, Rwanda), expansion of national CD4-based ART eligibility thresholds. However, even in 2011, men in our sample were more likely than women to enroll in care and initiate ART with advanced HIV disease, as previously described [4, 9, 17] . Importantly, despite declines in the proportion initiating ART with advanced HIV disease for both genders, the male-female disparity appears to be worsening with time. The reasons likely include that HIV-positive women may be more likely to engage in health-seeking behaviors resulting in HIV diagnosis and care linkage [18] , as well as the increased PMTCT scale-up and improved linkages between PMTCT and HIV care for women [19, 20] . In our sample, the proportion of patients who enrolled in care through PMTCT services doubled from 7% in 2006 to 14% in 2011, and those enrolling in care through PMTCT services had lower odds of initiating ART with advanced HIV disease.
Broad differences in the median CD4 count and trends over time were observed among sites in different countries, with a rapid increase in the median CD4 count at ART initiation at sites in Rwanda compared with sites in other countries. Several reasons could explain why patients at sites from Rwanda had uniformly higher median CD4 counts at ART initiation, including the implementation of a higher CD4 count threshold for ART eligibility in the national ART guidelines, lower patient caseload, higher provider to patient ratios, and early decentralization of services. Another recent study indicated that patients in Rwanda has the second highest mean CD4 count at ART initiation in the world (with the United States having the highest) [11] .
In multivariate models using longitudinal data from the pre-ART phase of care, we observed that patients who had a gap of ≥12 months in pre-ART care had twice the odds of initiating ART with advanced HIV disease. A systematic review of retention in HIV care prior to ART initiation in sub-Saharan Africa suggests that less than one-third of patients who test positive for HIV and are not eligible for ART at enrollment in care are retained continuously in care [21] . Providing incentives during HIV care, such as free cotrimoxazole, was shown in a small study to increase retention of such patients [22] . In an observational study, point-of-care CD4+ testing has been shown to reduce the median time between enrollment and ART initiation [23] and could therefore be an effective strategy to reduce pretreatment loss to follow-up and promote more timely ART initiation.
The strengths of this study include the incorporation of longitudinal data from the pre-ART phase of care and use of data derived from routine programs in a large number of HIV care and treatment clinics from a variety of facility types and settings in different regions of Kenya, Mozambique, Rwanda, and Tanzania. However, our results should be interpreted in light of certain limitations. The clinics included in this analysis, while part of national ART programs, are likely not representative of all clinics that provide HIV care and treatment in each of the 4 countries. The lack of interview data and information on the timing of HIV diagnosis and ART eligibility status at HIV diagnosis restricted our capacity to fully evaluate all the pathways leading to ART initiation when in the advanced stages of HIV disease. However, others are beginning to elucidate the potential underlying causes of late HIV presentation in the region, as in a recent study by Drain et al [13] . Finally, there were substantial missing data in our study, particularly CD4+ cell counts, both at enrollment in HIV care and at ART initiation, highlighting the importance of complete assessment of patients and documentation of clinical and laboratory findings. 
Conclusions
In conclusion, interventions are needed to diagnose HIV earlier, promote prompt linkage to HIV care, effectively enroll such individuals in continuous care and monitor them for ART eligibility, and, once eligible, to initiate them on ART in a timely manner. Without such efforts to promote earlier treatment initiation, the full potential for impact of HIV programmatic scale-up in the sub-Saharan African region may be diminished over the long term, in terms of both individual benefits and public health benefits of preventing onward HIV transmission.
Notes
